Results 51 to 60 of about 2,450,636 (325)

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies

PLoS Pathogens, 2013
Broadly neutralizing HIV antibodies (bnAbs) are typically highly somatically mutated, raising doubts as to whether they can be elicited by vaccination.
D. Sok, Uri Laserson, Jonathan Laserson, Yi Liu, Francois Vigneault, J. Julien, Bryan S. Briney, A. Ramos, Karen Saye, Khoa Le, Alison E. Mahan, Shenshen Wang, M. Kardar, Gur Yaari, L. Walker, B. Simen, Elizabeth P. St. John, P. Chan-Hui, K. Swiderek, S. Kleinstein, G. Alter, M. Seaman, A. Chakraborty, D. Koller, I. Wilson, G. Church, D. Burton, P. Poignard   +27 more
semanticscholar   +1 more source

Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study.

PLoS ONE, 2012
The HIV-1 envelope protein harbors several conserved epitopes that are recognized by broadly neutralizing antibodies. One of these neutralizing sites, the MPER region of gp41, is targeted by one of the most potent and broadly neutralizing monoclonal ...
Alexander Mader, Renate Kunert
doaj   +1 more source

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. [PDF]

PLoS ONE, 2011
Understanding the antibody response to HIV-1 in humans that show broad neutralizing serologic activity is a crucial step in trying to reproduce such responses by vaccination.
Hugo Mouquet, Florian Klein, Johannes F Scheid, Malte Warncke, John Pietzsch, Thiago Y K Oliveira, Klara Velinzon, Michael S Seaman, Michel C Nussenzweig   +8 more
doaj   +1 more source

Evaluating the neutralizing antibody response to HIV-1 membrane proximal external regional; Implications for vaccine design [PDF]

, 2014
Includes bibliographical references.Inducing broadly neutralizing antibodies targeting the HIV-1 envelope is thought to be crucial for developing an effective vaccine.
Jacob, Rajesh Abraham
core  

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA, Montefiori D.C., Pabst M., Pegu A., WHO   +4 more
core   +1 more source

Protein pyrophosphorylation by inositol pyrophosphates — detection, function, and regulation

FEBS Letters, EarlyView.
Protein pyrophosphorylation is an unusual signaling mechanism that was discovered two decades ago. It can be driven by inositol pyrophosphate messengers and influences various cellular processes. Herein, we summarize the research progress and challenges of this field, covering pathways found to be regulated by this posttranslational modification as ...
Sarah Lampe, Tanmay Kumar Mohanty, Rashna Bhandari, Dorothea Fiedler   +3 more
wiley   +1 more source

Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies

Viruses, 2009
The HIV/AIDS pandemic is one of the most devastating pandemics worldwide. Today, the major route of infection by HIV is sexual transmission. One of the most promising strategies for vaccination against HIV sexual infection is the development of a mucosal
Christiane Moog, Vincent Holl, Maryse Peressin   +2 more
doaj   +1 more source

Broad Neutralization by a Combination of Antibodies Recognizing the CD4 Binding Site and a New Conformational Epitope on the HIV-1 Envelope Protein [PDF]

, 2012
Two to three years after infection, a fraction of HIV-1–infected individuals develop serologic activity that neutralizes most viral isolates. Broadly neutralizing antibodies that recognize the HIV-1 envelope protein have been isolated from these patients
Feizi, Ten, Fätkenheuer, Gerd, Gaebler, Christian, Hurley, Arlene, Klein, Florian, Kraft, Zane, Lehmann, Clara, Liu, Yan, Morris, Lynn, Mouquet, Hugo, Nussenzweig, Michel C., Pietzsch, John, Poignard, Pascal, Sather, D. Noah, Scheid, Johannes F., Seaman, Michael S., Stamatatos, Leonidas, Walker, Bruce David   +17 more
core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study

BMC Infectious Diseases, 2003
Background Serological study of human papillomavirus (HPV)-antibodies in order to estimate the HPV-prevalence as risk factor for the development of HPV-associated malignancies in human immunodeficiency virus (HIV)-positive men.
Sarcletti Mario, Thaler Petra, Petter Anton, Höpfl Reinhard, Widschwendter Andreas, Zangerle Robert   +5 more
doaj   +1 more source